Respira Therapeutics, founded with a mission to revolutionize respiratory treatment, focuses on developing next-generation inhalation products for cardiopulmonary diseases. The company specializes in advanced particle engineering and formulation, combined with proprietary dry powder inhaler (DPI) technologies, to enhance drug delivery to the lung periphery. Their primary market focus includes patients suffering from pulmonary arterial hypertension (PAH), aiming to provide acute relief and improve overall respiratory health.

Notable figures affiliated with Respira Therapeutics include experts in respiratory medicine and pharmaceutical technology, although specific names are not provided. The company has attracted significant interest from investors in the healthcare sector, reflecting confidence in its innovative approach. Key achievements include the development of high-efficiency AOS DPI technologies, which have set new standards in drug delivery efficacy. Respira's impact is marked by its potential to significantly improve treatment outcomes for patients with severe respiratory conditions.